Blood test may predict transplant complication risk
NCT ID NCT04284904
First seen May 07, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study measured certain proteins in the blood of 500 people who had a stem cell transplant for blood cancer. The goal was to see if these proteins could help predict who might develop graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body. Researchers tracked protein levels every two weeks for three months after transplant and looked for links to GVHD and survival. This was an observational study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOMARKER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.